• The transcription factor activator protein AP is

  2023-09-26

  

  The transcription factor activator protein-1 (AP-1) is a redox-sensitive transcription factor whose activity is controlled by agents that perturb intracellular thiol concentrations [10,11]. AP-1 is mainly composed of Jun, Fos, and ATF protein dimers [12,13]. AP-1 mediates the regulation of numerous

• br Materials and methods br Results and discussion br Conclu

  2023-09-26

  

  Materials and methods Results and discussion Conclusion Introduction Free radicals produced by normal oxidative metabolism in the human body can cause chain oxidation of food, accelerate food deterioration and cause serious problems of food safety (Choe & Min, 2006). Excess free radicals

• br Conclusions br Transparency document br Acknowledgements

  2023-09-26

  

  Conclusions Transparency document Acknowledgements This work was supported by a grant from the European Commission FP6 “Neuroprion” – Network of Excellence and Royal Veterinary College Bioveterinary science research project funding. We thank Professor Alun Williams (Cambridge University) fo

• It has been known for a

  2023-09-26

  

  It has been known for a while that oxygenation (the addition of oxygen) of Aβ can inhibit the formation of amyloids and diminish their cytotoxicity. Photo-oxygenation of Aβ started with fullerenes almost a decade ago by Toshima and co-workers. Later, porphyrins and polyoxometalates were used as well

• br Concluding Remarks and Future Perspectives

  2023-09-26

  

  Concluding Remarks and Future Perspectives Herein, we have highlighted our current understanding of the role of the LKB1-AMPK pathway and its related kinases in β cell biology. β cell-specific genetic models have been particularly useful in delineating precise roles for individual family members

• br Experimental procedures br Results br Discussion br Ackno

  2023-09-26

  

  Experimental procedures Results Discussion Acknowledgments SRE and EBL contributed equally to this BMS 961 work. SRE, EBL, and MJT designed experiments, SRE, EBL, MCH, and AEI conducted experiments, SRE and EBL analyzed data, and EBL and MJT wrote the manuscript. We would like to thank

• Alectinib is a second generation

  2023-09-26

  

  Alectinib is a second generation ALK antagonist that is built upon a 9-ethyl-6, 6-dimethyl-11-oxo benzo[b]carbazole scaffold (Fig. 5C) [58]. This drug is effective against the ALK L1196M gatekeeper mutation along with C1156Y and F1174L mutations [7]. The 11-oxo group of the drug forms a GSK503 aust

• ALK fusion positive NSCLC is

  2023-09-26

  

  ALK fusion-positive NSCLC is clinically actionable because it can be targeted by several FDA-approved drugs, including the first generation TKI crizotinib, which is a dual inhibitor to MET and ALK [15], and the second generation inhibitors, alectinib and ceritinib, both of which are highly-selective

• The present work has implications for

  2023-09-26

  

  The present work has implications for our thinking about the effects of antidepressant (e.g. SSRIs) use on maternal care in depressed mothers which consist of approximately 10–20% of all mothers (Gjerdingen and Yawn, 2007, Susser et al., 2016), and more than 40% of depressed mothers are prescribed w

• br Introduction The chronic inflammation is one

  2023-09-26

  

  Introduction The chronic inflammation is one of the leading events involved in the aetiology of many chronic-degenerative diseases including diabetes, atherosclerosis, arthritis and cancer (Coussens and Werb, 2002). Monocytes/macrophages lineage plays an important role during inflammation through

• angiogenic br Results br Discussion Utilizing a proteomic

  2023-09-25

  

  Results Discussion Utilizing a proteomic approach, we identified HSP90β as a protein that becomes associated with surface AChR in agrin-stimulated muscle cells. We demonstrate that HSP90β does not interact with the AChR directly; instead, via direct interaction with rapsyn, HSP90β becomes asso

• The knowledge on the structure of CYP including its active

  2023-09-25

  

  The knowledge on the structure of CYP17, including its active site, provides a rationale for understanding many mutations that are found in enzyme dysfunction in clinical disease as well as the enzyme's dual hydroxylase and lyase catalytic capabilities. This knowledge will assist rational drug desig

• Matrix metalloprotease inhibitors are increasingly

  2023-09-25

  

  Matrix metalloprotease inhibitors are increasingly available and tested for other indications in clinical trials. The present study suggests that either ADAM10 or TACE inhibition alone will not maximally restore leukocyte Axl function. We found that lower doses of ADAM10/TACE inhibitors exhibit simi

• br Dual role of autophagy

  2023-09-25

  

  Dual role of autophagy in human diseases Emerging evidence suggests that autophagy serves as a double-edged sword in several human diseases, such as CNS diseases (Rubinsztein et al., 2015), arteriosclerosis (Schrijvers et al., 2011) and cancer (Ozpolat and Benbrook, 2015). Likewise, currently the

• chloride channels br Funding This study was supported

  2023-09-25

  

  Funding This study was supported by Grant UM1-CA186690 (NCI-CTEP) and R01CA204173 (CJB). This project used the UPCI Cancer Pharmacokinetics and Pharmacodynamics Facility (CPPF) and was supported in part by award P30-CA47904 and R50CA211241. Introduction Despite the efficacy of platinum based

15039 records 249/1003 page Previous Next First page 上5页 246247248249250 下5页 Last page